Nimesh Patel: Understanding Plasmapheresis – A Clinical Overview
Nimesh Patel, National Board Of Examinations in Medical Sciences at CKS Hospitals, shared a post on LinkedIn:
“Understanding Plasmapheresis: A Clinical Overview
Plasmapheresis—also known as therapeutic plasma exchange (TPE)—is a critical procedure used to remove large molecules such as pathogenic autoantibodies, immune complexes, or toxins from a patient’s plasma.
When the removal of circulating substances is required to halt or reverse disease progression, TPE becomes an essential intervention.
Key Clinical Indications
- Neurology: Myasthenia gravis, Guillain-Barré syndrome, and Chronic inflammatory demyelinating polyneuropathy (CIDP).
- Hematology: Thrombotic thrombocytopenic purpura (TTP) and Hyperviscosity syndrome.
- Nephrology: Anti-GBM disease (Goodpasture syndrome) and ANCA-associated vasculitis.
- Immunology and Other: Transplant rejection (ABO-incompatible) and Catastrophic antiphospholipid syndrome.
Potential Complications
While generally well-tolerated, the extracorporeal circuit and plasma replacement process carry inherent risks.
- Hypocalcemia: Commonly caused by citrate toxicity used for anticoagulation, which can lead to tingling, muscle cramps, or cardiac arrhythmias.
- Hypotension: Often related to volume shifts or patient sensitivity to the procedure.
- Infection/Access-related: Risks such as bacteremia or thrombosis associated with central venous catheter placement.
- Coagulopathy: Increased bleeding risk resulting from the removal of clotting factors.
- Allergic Reactions: Sensitivity to replacement fluids (e.g., albumin or fresh frozen plasma), ranging from mild urticaria to anaphylaxis.
Educational Disclaimer:
This content is intended for educational purposes only. Clinical decisions should always be individualized based on patient condition, clinical judgment, and institutional protocols.”

Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM